Discover upcoming drug launches under Trump's price control deals, CVS’s decision on Eli Lilly’s weight loss medication, and more pharmaceutical news.

Top of the morning to you. And a fine one it is here at the Pharmalot campus, where the official mascots are quietly snoozing now that our shortest person has returned to her out-of-town studies. As for us, we are downing another cup of stimulation — blueberry cobbler is our preference today. Feel free to join us.

The public is about to get its first look at the prices of drugs launched since President Trump struck his most-favored-nation deals with 17 drugmakers, STAT tells us. These deals require companies to launch new drugs in the U.S. at net prices roughly equal to those in other wealthy nations, though precise terms are secret. Three medicines set to launch in the coming months will provide the most public view yet of the practical impacts of Trump’s dealmaking: Baxfendy for hypertension from AstraZeneca, the insulin Awiqli from Novo Nordisk, and Veppanu, a cancer drug developed by Arvinas and Pfizer that is set to be licensed to Rigel Pharmaceuticals. Notably, Baxfendy and Veppanu are not yet available in other wealthy countries used as comparisons for reference pricing.

CVS Health will add Eli Lilly’s weight loss drug Zepbound back to some of its formularies on October 1 as an additional preferred option for insurance coverage, reports. Last July, Caremark, the CVS pharmacy benefit manager, had dropped the drug from its formularies while continuing to reimburse Wegovy, a rival drug from Novo Nordisk, after negotiating a more favorable price. Caremark will also remove a so-called new-to-market block on Lilly’s recently launched weight loss pill, Foundayo, as of June 1, where the drug is approved for coverage by health plans.

These changes reflect ongoing negotiations and adjustments in formularies to ensure competitive pricing and patient access. As these developments unfold, stakeholders are closely watching how they will impact both patients and pharmaceutical companies.

Stay tuned for more updates from as we continue to bring you the latest in pharmaceutical news.